Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction | MicrobiomeTrials← Back to trialsNCT04383262
Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-10-01Est. Completion: 2027-07-01
Enrollment target: 104 participants Locations- Froedtert Hospital, Milwaukee, Wisconsin, United States
Other microbiome trials you might be interested in
Gastroesophageal Reflux DiseaseEmotional Distress
The goal of this multicenter randomized waitlist-controlled clinical trial is to evaluate whether an online Mindfulness-…
Beijing, ChinaEst. completion May 15, 2028
Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD) is a chronic condition in which stomach acid flows back into the esophagus, causi…
Genova, ItalyEst. completion Jan 2027